Search

Displaying results 2751 - 2760 of 7602 in total
  1. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Acumapimod

    go.drugbank.com/drugs/DB15448
    Investigational

    Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers).

  3. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular

  5. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    The exact mechanism of action is still being investigated for all of the potential indications of agmatine. … Up to now (July 2013), the results of this study have not yet been published.

  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance

  7. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  8. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840).

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Thallous chloride

    go.drugbank.com/drugs/DB09316
    ApprovedWithdrawn

    It is used for diagnosis of heart and parathyroid problems. … The following are among the possible side effects: Blurred vision, chest pain or discomfort, chills, confusion, cough, difficulty with breathing, difficulty with swallowing, and dizziness.

  10. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells. Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF, which is a critical plasma glycop...